JCI Insight – MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF
ResearchIn-Press PreviewOncology Open Access | 10.1172/jci.insight.173688 Takahiro Utsumi,1 Yuki Shimizu,1 Ai Takemoto,1 Tomoko Oh-hara,1 Ken Uchibori,2 Sophia Subat-Motoshi,3 Hironori Ninomiya,3 Kengo Takeuchi,4 Makoto Nishio,2 Yasunari Miyazaki,5 and Ryohei Katayama1 1Cancer Chemotherapy Center,…